EC approves Cabometyx for advanced neuroendocrine tumors

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

Earlier this year, FDA announced that it would be initiating a voucher program aimed at accelerating review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, June 20, 2025).

October 24, 2025

Vol.51 No.39

By Claire Marie Porter

Clinical Roundup

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

A study led by University of Massachusetts Amherst researchers demonstrates that their nanoparticle-based vaccine can effectively prevent melanoma, pancreatic, and triple-negative breast cancer in mice.

October 17, 2025

Vol.51 No.38

KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill

In 1988, Frank McCormick learned with the rest of the field that more than 90% of patients with pancreatic cancer have a mutation in the Kirsten rat sarcoma viral gene.

Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

UT Southwestern Medical Center researchers have identified two distinct populations of cells known as antigen-presenting cancer-associated fibroblasts that appear to support the survival and growth of malignant tumors.

October 10, 2025

Vol.51 No.37

Funding Opportunities

Project Purple announces research grant to sustain pancreatic cancer studies that have been disrupted by federal funding policy changes

Project Purple, a national nonprofit dedicated to empowering the fight against pancreatic cancer, is launching the Pancreatic Cancer Research Recovery Support Grant. The initiative provides up to two years of bridge or rescue funding for promising pancreatic cancer research projects that were disrupted due to administrative funding policy changes at major federal agencies such as the NIH, the Department of Defense, or the National Science Foundation.

September 26, 2025

Vol.51 No.35

Drugs & Targets

EU CHMP issues two positive opinions for Keytruda

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted two positive opinions for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.

September 26, 2025

Vol.51 No.35

EC approves Cabometyx for advanced neuroendocrine tumors

YOU MAY BE INTERESTED IN

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

Nanoparticle vaccine prevents melanoma, pancreatic, and breast cancers in mice, study finds

KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill

Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

Project Purple announces research grant to sustain pancreatic cancer studies that have been disrupted by federal funding policy changes

EU CHMP issues two positive opinions for Keytruda

Renew today!

Subscriber content

Never miss an issue!

Login